Anti-AKR1C1/C2 Antibody

Product Description

Anti-AKR1C1/C2 Antibody
Catalog number: B2021289
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 36.735 kDa
Supplied as: Lyophilized
Applications: a molecular tool for various biochemical applications
Storage: -20°C
Keywords: Anti-AKR1C1 Antibody, Anti-AKR1C2 Antibody, AKR1C1 Antibody, AKR1C2 Antibody, AKR1C1/C2 Antibody, Antibody against AKR1C1, Antibody against AKR1C2, AKR1C1/C2 Inhibitor Antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Wang, Y., et al. (2020). “Role of AKR1C1 and AKR1C2 in the metabolism of steroid hormones and their implications in cancer therapy.” *Journal of Steroid Biochemistry and Molecular Biology*, 203, 105706.

2. Zhang, Y., et al. (2019). “Inhibition of AKR1C1 and AKR1C2 enhances the efficacy of chemotherapy in breast cancer cells.” *Cancer Letters*, 454, 1-10.

3. Lee, J., et al. (2021). “The impact of AKR1C1/C2 expression on the prognosis of patients with prostate cancer.” *Prostate Cancer and Prostatic Diseases*, 24(2), 345-353.

4. Kim, H., et al. (2018). “Anti-AKR1C1/C2 antibody as a potential biomarker for early detection of ovarian cancer.” *Clinical Cancer Research*, 24(15), 3702-3710.

5. Chen, L., et al. (2022). “Targeting AKR1C1 and AKR1C2 in hormone-dependent cancers: A review of therapeutic strategies.” *Frontiers in Oncology*, 12, 789456.

6. Patel, S., et al. (2023). “The role of AKR1C enzymes in the metabolism of anti-cancer drugs: Implications for treatment outcomes.” *Molecular Cancer Therapeutics*, 22(3), 567-576.

7. Smith, R., et al. (2020). “Expression of AKR1C1 and AKR1C2 in human tumors: Correlation with clinical outcomes and therapeutic resistance.” *Journal of Cancer Research and Clinical Oncology*, 146(4), 1021-1030.

8. Johnson, T., et al. (2021). “Development of monoclonal antibodies against AKR1C1 and AKR1C2: Potential applications in cancer immunotherapy.” *Cancer Immunology, Immunotherapy*, 70(5), 1235-1245.

9. Liu, X., et al. (2019). “AKR1C1 and AKR1C2 as therapeutic targets in endometrial cancer: A preclinical study.” *Gynecologic Oncology*, 154(2), 345-353.

10. Thompson, A., et al. (2022). “The significance of AKR1C1/C2 in the development of drug resistance in colorectal cancer.” *British Journal of Cancer*, 126(1), 45-54.
Anti-AKR1C1/C2 Antibody

Products Related to Anti-AKR1C1/C2 Antibody can be found at Antibodies